The study, sponsored by the University of Alberta, aims to evaluate the efficacy of immunoglobulin replacement therapy (IRT) in patients experiencing hypogammaglobulinemia (HGG) following CD19-targeted CAR T cell therapy. With a growing market for CAR T therapies and increasing recognition of the complications associated with B cell depletion, this trial addresses a critical unmet need in infection prevention for these patients. The outcomes may inform future guidelines and treatment protocols, potentially enhancing the commercial viability of immunoglobulin products. The competitive landscape includes other immunoglobulin therapies, but the unique focus on CAR T-related HGG may provide a niche market opportunity. Diligence should consider the regulatory landscape for immunoglobulin therapies and the potential for partnerships with CAR T manufacturers.